DIRS.INFO The most relevant business & tech news

☆ Oppenheimer's top stock picks heading into year-end
▼ + stars: | 2024-11-20 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Meanwhile, the Dow Jones Industrial Average and the S & P 500 are each up more than 3% month to date. As November nears its close, Oppenheimer has updated its top stock ideas list. Its $145 price target reflects almost 22% upside from Tuesday's close. Oppenheimer believes medical technology company Transmedics is also due for a rally, as its $125 target reflects nearly 51% upside from Tuesday's close. TMDX YTD mountain TMDX, year-to-date For newly added Citigroup, Oppenheimer's $107 target implies more than 56% upside from Tuesday's close.

Persons: Stocks, Donald Trump's, Oppenheimer, Rob Lynch, Brian Bittner, Suraj Kalia Organizations: Oppenheimer, Nasdaq, Dow Jones Industrial, Citigroup, Oppenheimer's Locations: Instacart

Global medical technology company GE HealthCare is an "attractive large-cap diagnostics & imaging play," according to Oppenheimer. The firm says GE HealthCare has become more focused following its recent spinoff from its parent company. "GE Healthcare is the global leader in healthcare diagnostics, imaging, and intervention. "Its medium-term margin outlook is predicated on key initiatives," including optimizing manufacturing, introducing new products and integrated digital solutions, Kalia said. The analyst noted that GE HealthCare looks to benefit from an aging population and increase in chronic diseases.

☆ Medical device stocks tend to beat the market, and analysts expect these names to see big gains
▼ + stars: | 2023-01-23 | by ( Bertha Coombs | ) www.cnbc.com time to read: +4 min

Medical device makers, like many manufacturers, have faced challenges over the last year from inflationary supply chain costs, staffing shortages and the strong dollar impacting sales overseas. However, since 2007 the device sector ETF has averaged a gain of 14% per year, 6 percentage points better than the broader market index over the same period. More than 60% of analysts rate the shares a buy, with a mean price target implying 34% upside. Nearly 90% of analysts rate the stock a buy, with mean price target of $53, implying more than 30% upside. BTIG analysts Marie Thibault and Ryan Zimmerman think that M & A could be another catalyst for the medical device sector in 2023, with robotic surgery players likely to be of particular interest.

Search resuls for: "Suraj Kalia"

3 mentions found